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Abstract
According to the Centers for Disease Control and Prevention, prescribers should evaluate
risk factors related to opioid use prior to initiation of opioid medication. The practice
problem in this DNP project was that providers failed to consistently assess patients with
complaints of pain for risk of opioid misuse and/or abuse prior to initiating opioid
medication. An opioid risk-assessment screening tool (ORAST) has the potential to
identify patients at high risk for opioid misuse and/or abuse. The purpose of this Doctor
of Nursing Practice project was to identify and introduce an ORAST and then develop a
policy to guide providers in its use in an ambulatory care clinic. Rosswurm and
Larrabee’s model for evidence-based practice served as the framework that helped guide
project development. Evidence in the literature review supported The Opioid Risk Tool
(ORT) as the most appropriate tool for the clinic. An 11-member project team voted
unanimously for the ORT and to develop a policy to guide the use of the tool in the
clinic. The ORT and its policy were evaluated by the team using the AGREE II
Instrument. The team agreed that the ORT and its policy should be implemented into
their practice setting (64% strongly agreed and 36% moderately agreed). A summative
evaluation supported the Doctor of Nursing Practice student leadership of the project.
Use of an ORAST has the potential to create positive social change by reducing the
number of prescribed opioid by assisting providers in determining a patient’s plan of care
based on the patient’s level of risk for prescription opioid misuse and/or abuse. Patient
outcomes may be improved through reduction in opioid misuse and/or abuse.

Evaluation of an Opioid Risk-Assessment Screening Tool
by
Jacquelyne M. Guerra

Project Submitted in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Nursing Practice

Walden University
February 2018

Dedication
I would like to dedicate my doctoral research to my best friend and husband.
Together we will always be superheroes. I am now ready to write our next chapter
together.

Acknowledgments
I would like to express my deepest appreciation and indebtedness particularly to
Dr. Cheryl McGinnis. Thank you for your endless support, mentorship, understanding,
and kindness throughout my doctoral studies.
I would also like to declare my undying thankfulness to Mr. Anthony Guerra.
Through this process you have been my rock and the cornerstone of my very being. No
matter how great the task at hand, your belief in me to make astounding accomplishments
despite all odds is unwavering.

Table of Contents
Section 1: Overview of the Evidence-Based Project ...........................................................1
Introduction ....................................................................................................................1
Problem Statement .........................................................................................................4
Purpose...........................................................................................................................6
Nature of the Doctoral Project .......................................................................................7
Significance....................................................................................................................8
Summary ........................................................................................................................9
Section 2: Background and Context ..................................................................................11
Introduction ..................................................................................................................11
Concepts, Models, and Theories ..................................................................................12
Rosswurm and Larrabee’s Model for Evidence-Based Practice..................................13
Definitions of Key Terms ............................................................................................14
Relevance to Nursing Practice .....................................................................................15
Local Background and Context ...................................................................................18
Role of the DNP Student..............................................................................................19
Role of the Project Team .............................................................................................21
Summary ......................................................................................................................23
Section 3: Collection and Analysis of Evidence ................................................................24
Introduction ..................................................................................................................24
Practice – Focused Question ........................................................................................25
Sources of Evidence .....................................................................................................25
i

Systematic Review of the Literature ............................................................................26
Selecting Opioid Risk-Assessment Screening Tool ............................................. 27
Validation, Sensitivity, and Specificity of Opioid Risk Assessment
Screening Tools ........................................................................................ 28
Barriers to Implementing an Opioid Risk Assessment Tool ................................ 32
Opioid Risk-Assessment Screening Tools ............................................................ 34
Opioid Risk Tool................................................................................................... 35
The Screening Instrument for Substance Abuse Potential .................................... 36
The Screener and Opioid Assessment for Patients with Pain – Revised .............. 37
The Diagnosis, Intractability, Risk, Efficacy ........................................................ 40
Recommended Guidelines for the Treatment of Chronic Pain ............................. 41
Recommending an Opioid Risk-Assessment Screening Tool .....................................43
Inclusion Criteria .................................................................................................. 44
Exclusion Criteria ................................................................................................. 45
Ethical Considerations .................................................................................................47
Analysis and Synthesis ................................................................................................47
Summary ......................................................................................................................48
Section 4: Findings and Recommendations .......................................................................49
Doctoral Project Team .......................................................................................... 50
Stakeholder Process and Policy Development .............................................................50
Findings and Implications ............................................................................................54
Appraisal of Guidelines Research and Evaluation (AGREE) II Instrument......... 54
ii

Summative Evaluation of DNP ............................................................................. 57
Potential Implications for Positive Social Change................................................ 60
Strengths and Limitations of the Project ......................................................................60
Recommendations ........................................................................................................62
Summary ......................................................................................................................65
Section 5: Dissemination Plan ...........................................................................................66
Introduction ..................................................................................................................66
Analysis of Self ............................................................................................................66
As a Practitioner .................................................................................................... 66
As a Scholar .......................................................................................................... 67
As a Project Developer ......................................................................................... 67
Project Completion ............................................................................................... 67
Summary ......................................................................................................................69
References ..........................................................................................................................71
Appendix A: Opioid Risk Tool ..........................................................................................77
Appendix B: Disclosure to Expert Panelist Form for Anonymous Questionaires……….78
Appendix C: AGREE II Instrument……………………………………………………...79
Appendix D: Summative Evaluation…...………………………………………………..80
Appendix E: Opioid Risk Tool Policy…………………………………………………...81

iii

1
Section 1: Overview of the Evidence-Based Project
Introduction
The United States is presently facing an opioid epidemic due to the cultural shift
related to opioid prescribing that started approximately two decades ago which
encompassed over 259 million opioids being prescribed in 2012 (Sengal, Manchikanti, &
Smith, 2012). This equates to one bottle for every adult in America. According to the U.S
Department of Health and Human Services (2017), on average 650,000 opioid
prescriptions are written daily. The Center for Disease Control and Prevention (CDC,
2017), has reported that opioid-related deaths have quadrupled since 1999.
One of the main ways to reduce opioid misuse, abuse, addiction, dependence and
related deaths is to ensure proper opioid prescribing. According to the CDC (2017),
proper opioid prescribing means that providers follow three categories of evidence-based
recommendations. Providers must give careful consideration (a) about when to initiate or
continue opioid management for chronic pain, (b) to opioid selection, dosage, duration,
follow-up and discontinuation; and (c) assessing patients’ risk and addressing the
potential harm of opioids. Currently, at an inner city ambulatory care clinic (the clinic
under study) providers do not consistently assess patients for potential risk of opioid
misuse and/or abuse prior to initiating opioids in patients with complaints of pain. One
way to consistently assess patients for potential opioid misuse and/or abuse is to screen
them with an opioid risk-assessment screening tool.
The practice problem in this DNP project was that providers failed to consistently
assess patients with complaints of pain for risk of opioid misuse and/or abuse prior to
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initiating opioid medication. This clinic sees about 3,000 patients annually, 30% of which
are seen for noncancer-related pain complaints (S. Cole, personal communication, March
10, 2017). A large number of these patients have a history of aberrant behaviors, of
physical and/or sexual abuse, of psychological illness, and/or family history of substance
abuse (S. Cole, personal communication, April 21, 2017). According to Passik (2008),
these factors have the potential to increase a patient’s risk of opioid misuse and/or abuse.
In the United States over 5,000 individuals abuse opioids for the first time each day,
while more than 100 die from opioid-related overdoses daily (Barrus, Averil, Sudweck,
Averil, and Mota, 2016). The number of opioid prescriptions written varies from state to
state, but according to the CDC (2014), Connecticut prescribed 73 opioid prescription
pain killers per 100 people in 2012, while surrounding states ranged from 52-71 painkiller prescriptions per 100 people, excluding Rhode Island which prescribed 90 painkiller prescriptions per 100 people.
Current evidence-based guidelines for prescribing opioids recommend than an
opioid risk-assessment screening tool (ORAST) be used prior to the initiation of
prescribing opioids for patients with complaints of pain in order to assess for risk of
opioid misuse and/or abuse. According to the CDC (2017), improving prescribing
practices for opioids includes strategies to (a) reduce exposure to opioids, (b) prevent
abuse, (c) prevent misuse, and (d) stop addiction and dependence. This includes
implementing the use of opioids as a last resource after other treatment modalities have
failed. According to Cheattle (2017), guidelines recommend that providers prescribing
opioids first assess patients using an ORAST. Additionally, the CDC (2016) reported that

3
evidence-based guidelines include evaluating risk factors related to opioid use prior to the
initiation of opioid medication management. An ORAST has the potential to identify
those patients at high risk for opioid misuse and/or abuse. According to Passik, Kirsh,
and Casper (2008), opioid risk-assessment screening tools can help providers identify
high-risk patients for misuse and/or abuse, and then monitor and adjust their opioid
treatment accordingly. They would allow providers to avoid initiating opioid medication
management to patients who have high-risk stratification. A provider may not want to
prescribe to a patient with a high-risk stratification as that patient has an increased
probability of misusing and/or abusing opioid medications. Doing so can yield adverse
outcomes up to, and including death. Additionally, an ORAST can help providers select
the frequency and intensity of adherence monitoring during opioid medication
management.
Addressing this practice problem is both meaningful and relevant to this innercity ambulatory care clinic. The DNP project introduced clinic providers to a
comprehensive ORAST for use in identifying patients at risk for opioid misuse and/or
abuse prior to initiating opioid medications. Identifying at-risk patients will allow
providers to make a comprehensive assessment as to whether initiating opioids is
appropriate for their patient, including the potential risks and benefits of opioid use for
the patient with complaint of pain.
The purpose of this Doctor of Nursing Practice project was to identify and
introduce an ORAST and then develop a policy to guide providers in its use in an
ambulatory care clinic. Opioid-related aberrant behaviors include nonadherence to

4
medical dosing, nonadherence to the treatment plan, attempts to refill opioid medications
early, misplacing opioid medications, and illegally obtaining and distributing opioid
medications. Introducing an ORAST in this inner-city ambulatory clinic in the northeast
of the United States will help to reduce opioid exposure, misuse, abuse, dependence,
addiction, subsequent deaths by identifying patients at risk for opioid misuse and/or
abuse. When providers screen patients at risk for misuse and/or abuse, fewer opioid
prescriptions may be written, and patient adherence monitoring can be implemented as a
strategy to decrease the number of patients misusing and abusing prescription opioids.
Problem Statement
The practice problem in this DNP project was that providers failed to consistently
assess patients with complaints of pain for risk of opioid misuse and/or abuse prior to
initiating opioid medication. Individuals with complaints of chronic pain and cooccurring substance use disorders, and/or mental illness are at a higher risk for opioid
misuse and abuse (Sehgal, Manchikanti, & Smith, 2012). This clinic serves a patient
population that is known to have a history of aberrant behaviors, physical and/or sexual
abuse, psychological illness, and/or a family history of substance abuse (S. Cole, personal
communication, April 21, 2017). These factors have the potential to increase a patient’s
risk for opioid misuse and/or abuse (Passik, Kirsh, & Casper, 2008). The gap in practice
was that, despite guidelines that recommend evaluating risk factors related to opioids
prior to the initiation of opioid medication, providers continued to prescribe them without
consistently assessing the patients. As a result, high-risk patients being seen in the clinic
for complaints of pain are being prescribed opioids without an appropriate opioid risk-
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assessment. These high-risk patients are not being adequately screened for potential
aberrant behaviors before receiving a prescription for an opioid. Strategies to mitigate
against opioid misuse and/or abuse include using (a) opioid risk-assessment screening
tools to identify patients with substance abuse disorders, (b) data from the Prescription
Monitoring Drug Program, (c) urine drug screening, and (d) provider-patient adherence
contracts (Volkow & McLellan, 2016). The major source of diverted opioids is provider
prescriptions, and opioid analgesics are the most widely diverted and improperly used
medication in the United States (Volkow & McLellan, 2016).
In April of 2017, among the 10 resident-based primary care teams at the clinic, 92
patients were documented as being actively managed on opioids for chronic pain
complaints (S. Cole, personal communication, April 21, 2017). Of those 92 patients,
approximately 70% had a diagnoses or a history of mental illness and/or substance abuse
disorders (S. Cole, personal communication, April 21, 2017). A critical component of
preventing opioid misuse and/or abuse is being able to identify patients who are at risk
for these aberrant behaviors.
This doctoral nursing project holds significance for nursing practice as it
addresses the importance of using an ORAST to identify patients at risk for opioid misuse
and/or abuse in the outpatient ambulatory clinic. Although this particular clinic does not
use nurse practitioners in their outpatient ambulatory care clinic, they may do so in the
future. Within the state, nurse practitioners provide direct patient care within a variety of
clinical settings and specialties. Nurse practitioners are commonly used to address the
growing demand for primary care providers either by working independently or in
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collaboration with a physician. According to the Department of Public Health (2017), in
Connecticut nurse practitioners are able to either independently or in collaboration with a
physician practice within the full extent of their scope including prescribing, dispensing,
and administering medications.
This doctoral project is expected to guide nurse practitioners on the use of an
opioid risk-assessment screening tools in outpatient ambulatory clinics. Nurse
practitioners who adapt the current evidence guidelines and use an ORAST prior to
initiating opioids can identify patients at high risk for misuse and/or abuse. By
completing a comprehensive risk assessment on patients with complaints of pain, nurse
practitioners can tailor each patient’s plan of care based on individualized risk
stratification in order to manage pain complaints with taking the least amount of risk. For
patients identified as being at high risk for opioid misuse and/or abuse, the result may be
deferring from initiating opioids and starting a trial of alternative therapies, initiating
opioids with intensified adherence monitoring, and/or referring to a specialist in pain
management. Using an ORAST can help providers to include nurse practitioners reduce
prescription opioid related abuse, misuse, exposure, dependence, addiction, and overdose.
Purpose
The purpose of this Doctor of Nursing Practice project was to identify and
introduce an ORAST and then develop a policy to guide providers in its use in an
ambulatory care clinic. Currently, providers in the inner-city, ambulatory care clinic, in
the northeastern United States continue to prescribe opioids without first completing a
comprehensive opioid risk-assessment on patients with complaints of pain. The practice-
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focused question was as follows: “Will the introduction of an opioid risk-assessment
screening tool and the policy to guide provider use help in identifying patients at risk for
opioid misuse and/or abuse?”
Nature of the Doctoral Project
Peer-reviewed, research articles published within the past 10 years were reviewed
as apart of a comprehensive, systematic approach to the literature review on opioid riskassessment. Although older than 10 years, some articles were included because they
evaluated the selected opioid risk-assessment screening tools in terms of sensitivity and
specificity. The following databases were used: PubMed, Ovid, Medline, and the CDC.
Additionally, the Boolean search of key words was applied when reviewing the sources
of evidence. The following keywords were used: addiction assessment tool and
compliance, predicting aberrant behavior and opioids, opioid prescribing. I used
Boolean operators, AND and OR, to optimize the results.
The strategy utilized to obtain the evidence needed to complete this doctoral
project included completing an integrated literature review and critically appraising the
strength of evidence to recommend an ORAST to clinic providers. The recommended
ORAST was presented to the team. A policy was developed with the team based on the
needs of the clinic. The ORAST and the policy to guide providers in using it was then
presented to, and evaluated by, the team using the AGREE II Instrument. Team members
were then asked to provide a summative evaluation of the DNP student learning
leadership within the project.
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Significance
The stakeholders that have been identified for the purpose of this DNP quality
improvement project are the medical director and one resident from each primary care
team. The medical director’s role within the clinic in addition to patient care is
overseeing the clinic’s day-to-day operations to include facilitating policy changes based
on evidence-based practice guidelines. Additionally, he serves as an attending for the
residents, which includes supervising, teaching, and training them. This inner-clinic
ambulatory care clinic divides its primary care patients amongst 10 resident-based
primary care teams. Each team has between three and four residents assigned to it at any
given time. The resident from each team was chosen to participate by the medical
director. Stakeholder criteria for selection included availability to attend all meetings,
provide feedback on the selected ORAST and the developed policy guiding its use, and a
willingness to serve as a positive social change agent within the clinic. I served as the
pain management expert on the team.
It is expected that this doctoral project will contribute to nursing practice in four
ways: (a) If nurse practitioners use it, it could improve patient safety and prevent deaths;
(b) It could change the primary care providers’ management of patients with complaints
of pain; (c) It could change prescribing practices within the clinic; (d) It could create
positive social change by identifying patients at risk for opioid misuse and/or abuse prior
to initiating opioid treatment, reduce the amounts of opioids that are prescribed, decrease
opioid misuse, abuse, dependence, addiction, and opioid-related deaths, and the
associated economic burden.
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Recommendations included the selection of an ORAST applicable to the clinic’s
patient population and the development of a policy to guide providers’ use of the opioid
risk-assessment screening tool. Stakeholders completed the AGREE II Instrument and
provided summative evaluation of the project. Revisions were made based on stakeholder
evaluations. Implementation of the tool and policy will occur after graduation. The
project has the potential to change the primary care provider’s management of patients
with complaints of pain. The patient’s plan of care can include the risk-benefit analysis of
initiating opioid medications, and determinants of adherence monitoring if the provider
chooses to move forward with initiating opioid medication therapies.
Utilization of an ORAST has the potential to change prescribing practices within
the clinic and create positive social change by reducing the amount of opioids that are
prescribed, and tailor adherence monitoring specifically to each patient’s risk
stratification through a policy to guide providers in the use of the tool. This DNP project
is translating the evidence into practice through application of an opioid risk-assessment
screening tool. Limiting the amount of opioids that are prescribed and identifying patients
at risk for opioid misuse and/or abuse prior to initiating opioid management may decrease
opioid misuse, abuse, dependence, addiction, opioid related deaths and the associated
societal economic burden.
Summary
The practice problem in this DNP project was that providers failed to consistently
assess patients with complaints of pain for risk of opioid misuse and/or abuse prior to
initiating opioid medication. The gap in practice was that, despite guidelines that
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recommend evaluating risk factors related to opioids prior to the initiation of opioid
medication, providers continued to prescribe them without consistently assessing the
patients. The practice-focused question was as follows: “Will the introduction of an
opioid risk-assessment screening tool and the policy to guide provider use help in
identifying patients at risk for opioid misuse and/or abuse?”
The purpose of this DNP project was to identify and introduce an ORAST and
then develop a policy to guide providers in its use in an ambulatory care clinic. This
doctoral nursing project holds significance for the field of nursing practice as it has the
potential to guide nurse practitioners on the use of an ORAST so patients at risk for
opioid misuse and/or abuse are identified and alternative treatment methods offered.
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Section 2: Background and Context
Introduction
The practice problem in this DNP project was that providers failed to consistently
assess patients with complaints of pain for risk of opioid misuse and/or abuse prior to
initiating opioid medication. In April of 2017, 92 patients were prescribed opioids within
the clinic (S. Cole, personal communication, April 21, 2017), none of which had been
screened for risk of opioid misuse and/or abuse using an ORAST prior to initiating opioid
management by the provider. Evidence-based guidelines for prescribing opioids stipulate
that providers must assess patients for risk of aberrant behavior prior to initiating opioid
medications. Of all patients prescribed opioid medications, 50% of patients do not take it
as prescribed; this in turn, inflates health costs (Walghmare, Lelito, Detscher, & Salcedo,
2017). Predicting the risk of aberrant opioid drug-related behaviors may help providers in
developing a treatment plan that includes deterring prescribing opioids for a patient at
high risk for abuse and/or misuse and the amount of rigidity needed to monitor for
treatment adherence if opioids are initiated (Chou, Fanciullo, Fine, Miaskowski, Passik,
& Russel, 2009). In 2007 it was estimated that 12.5 million Americans used opioid pain
relievers for nonmedical purposes, and approximately 1.7 million of them met the
diagnostic criteria for abuse or dependence (Birnbaum, White, Schiller, Waldman,
Cleveland, & Roland, 2011). In 2007 it was found that opioid prescription abuse in the
United States accounted for $25.6 billion in workplace costs, $25.0 billion in healthcare
costs, and $5.1 billion in criminal justice costs (Birnbaum et al., 2011). Developing risk
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evaluation and mitigation strategies in support of initiating opioid medication can reduce
the societal and economic burden associated with misuse and/or abuse.
The practice-focused question was as follows: “Will the introduction of an opioid
risk-assessment screening tool and the policy to guide provider use help in identifying
patients at risk for opioid misuse and/or abuse?” The purpose of this DNP project was to
identify and introduce an ORAST and then develop a policy to guide providers in its use
in an ambulatory care clinic.
In the next section, I discuss the theoretical framework used to inform this
doctoral project, the relevance of this doctoral project to nursing practice, the local
background and context, and the role of the DNP student.
Concepts, Models, and Theories
Translation of evidence into current practice is essential in order to improve
patient outcomes, patient safety, and the quality of the healthcare provided. A conceptual
model or framework guides the implementation of evidence-based practice (White,
Dudley-Brown, & Terhaar, 2012). The model used to guide and inform this DNP project
is Rosswurm and Larrabee’s model for evidence-based. The six steps of this model
include assessing the need for change in practice by comparing internal data with
external data, linking the problem with interventions and outcomes, synthesizing the best
evidence, designing a change in practice, implementing and evaluating the change in
practice (including processes and outcomes), and integrating and maintaining the change
in practice using diffusion strategies (White, Dudley-Brown, & Terhaar, 2012).
According to Pipe (2007), Rosswurm and Larrabee’s model for evidence-based practice
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is versatile for translating evidence-based practice into practice in order to optimize the
level and quality of patient care.
Rosswurm and Larrabee’s Model for Evidence-Based Practice
Rosswurm and Larabee’s conceptual framework guides nurses through a
systematic process to translate research into practice (Pipe, Wellik, Buchda, Hansen, &
Martyn, 2005). The first of the six steps is to assess the need for change in practice. This
includes speaking with and building relationships with key stakeholder, collecting data
about the current practice setting and then comparing the internal data with external data
in order to identify a practice problem.
The second step is to link the problem, intervention, and outcomes. According to
Wellil, Buchda, Hansen, and Martyn (2005), through utilization of classification systems
and language potential interventions and activities are identified. Thereafter outcome
indicators can be selected. The third step of the Rosswurn and Larrabee’s model for
evidence-based practice is to synthesize the best evidence. This is done through a
comprehensive review of the literature, evaluating and critiquing the evidence,
synthesizing the best evidence, and moving forward to assessing the feasibility, benefits,
and the risks of the evidence that was synthesized (Wellil, Buchda, Hansen, & Martyn
2005).
The fourth step is to design a practice change. According to Wellil, Buchda,
Hansen, and Martyn (2005), this step includes defining the proposed change, identifying
any needed resources to support the change, plan the implementation of the practice
change, and finally defining outcomes. Implementing and evaluating the change in
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practice is the fifth step of Rosswurm and Larrabee’s model for evidence-based practice.
According to Wellil, Buchda, Hansen, and Martyn (2005), this step includes using a pilot
study demonstration, evaluating the process and outcomes, and finally to decide to adapt,
adopt, or reject the practice change. The final and sixth step of Rosswurm and Larrabee’s
model for evidence-based practice change is to integrate and maintain the practice
change. According to Wellil, Buchda, Hansen, and Martyn (2005), this includes
communicating the recommended change to stakeholders, present staff in-service
education on the practice change, integrate the practice change into the standards of
practice, and finally to monitor process and outcomes.
Definitions of Key Terms
For the purpose of this DNP project the following key terms have been defined in
order to clarify any terms that may have multiple meanings in related to opioids.
Adherence monitoring: methods in clinical practice utilized to identify
problematic drug use from onset through continuation of opioid management
(Matteliano, Marie, & Olive, 2014).
Noncancer pain: pain that can be acute or chronic in nature but is not related to an
underlying cancerous pathology.
Opioid abuse: is the non-medical use of an opioid medication repeatedly, or
sporadically for the psychoactive affects that they produce (Hahn, 2011).
Opioid misuse: is using the prescription opioid for other than which it was
prescribed (Hahn, 2011).
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Opioid related aberrant behaviors: include non-adherence to medical dosing,
non-adherence to the treatment plan, attempts to refill opioid medications early,
misplacing opioid medications, and obtaining and distributing opioid medications.
Opioid risk-assessment screening tool: measure factors involved in a patient’s
overall level of risk of misusing and/or abusing opioids.
Providers: refers to anyone rendering medical care to include physicians,
physician assistants, and nurse practitioners.
The key difference between opioid misuse and opioid abuse is with opioid misuse
the opioid medication is not being taken for an intentional euphoric affect. Examples of
opioid misuse include taking more of less of the prescribed opioid at different intervals
other than the way it was prescribed, using the opioid medication for other conditions that
the condition it was prescribed for.
Relevance to Nursing Practice
According to Hahn (2011), the use of prescription opioid medications has the
potential to lead to patient’s misusing and/or abusing these medications as well as
becoming addicted or dependent on them and possibly diverting them to others.
According to Hahn (2011), the healthcare costs for an opioid abuser is eight times higher
than a non-opioid abuser while the retail sales of opioid medications have skyrocketed.
Between 1997 and 2006 the sales of hydrocodone has increased by 244%, oxycodone by
732%, and methadone by 1177% (Hahn, 2011). The total United States societal costs for
prescription opioid abuse were estimated to be $55.7 billion in 2007.
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According to the CDC (2016), improving prescribing practices for opioids
includes strategies to reduce exposure to opioids, prevent abuse, prevent misuse, and stop
addiction and dependence. Current evidence-based guidelines include evaluating risk
factors related to opioid use prior to initiation of opioid medication management. An
ORAST has the potential to identify those patients at high risk for opioid misuse and/or
abuse (CDC, 2016). In 2007, it was estimated that 5.2 million people aged 12 or older
abused prescription opioids in the previous month. According to Chou, Fanciullo, Fine,
Miaskowski, Passik, and Russel (2009), predicting the risk of aberrant opioid drugrelated behaviors may help providers develop an opioid treatment plan to include to deter
prescribing opioids for a patient at high risk for misuse and/or abuse and the amount of
rigidity needed to monitor for treatment adherence if opioids are initiated.
The development of theories and translation of research into nursing practice
allows evidence-based practices to be implemented in order to improve patient outcomes.
According to White, Dudley-Brown, and Tehaar (2016), translating evidence into routine
clinical practice is pivotal to ensure quality care however, despite data that has been
generated from rigorous research studies takes more than 17 years for research findings
to be implemented into daily practice. By that factor alone the scientific underpinnings of
health care practices will remain outdated while current research remains available and
waiting to be implemented. Doctoral prepared nurses must be leaders in the discipline of
nursing and overall healthcare. The responsibilities of a DNP prepared nurse includes
being able to appraise research, identify evidence-based practice, assess gaps in health
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care, and implement these findings into practice in order to improve patient care. This
DNP project addresses each of the eight DNP Essentials (AACN, 2006).
•

Scientific Underpinnings for Practice

•

Organization and Systems Leadership for Quality Improvement and Systems
Thinking

•

Clinical Scholarship and Analytical Methods for Evidence-Based Practice

•

Information Systems/Technology and Patient Care Technology for the
Improvement and Transformation of Health Care

•

Health Care Policy for Advocacy in Health Care

•

Interprofessional Collaboration for Improving Patient and Population Health
Outcomes

•

Clinical Prevention and Population Health for Improving the Nation’s Health

•

Advanced Nursing Practice

According to the American Association of Colleges of Nursing (2006), Advanced
Practice Nurses assess, manage, and evaluate patients at the most independent level of
clinical nursing practice by utilizing highly refined assessment skills while being able to
make improvements in their particular patient populations in the systems within which
they practice. The development of a policy to guide the use of an ORAST can be
implemented by nurse practitioners in outpatient ambulatory clinics to improve the
quality and safety of care provided to patients within the clinic with complaints of pain.
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Local Background and Context
The practice-focused question was as follows: “Will the introduction of an opioid
risk-assessment screening tool and the policy to guide provider use help in identifying
patients at risk for opioid misuse and/or abuse?” Prescription opioid medications are
highly diverted and improperly used in the United States (Volkow & McLellan, 2016). In
2014, 245 million prescription opioids were dispensed in America (Volkow & McLellan,
2016). This is feeding the national opioid epidemic that we are facing resulting in opioid
overdose deaths, dependence, addiction, and the skyrocketing societal burden. According
to the CDC (2016), improving prescribing practices for opioids includes strategies to
reduce exposure to opioids, prevent abuse, prevent misuse, and stop addiction and
dependence. Current evidence-based guidelines for prescribing opioids recommend that
an opioid risk-assessment be completed prior to the initiation of prescribing opioids for
patients with pain in order to assess for risk of opioid misuse and abuse.
According to Jones, Moore, Levy, Daffaron, Browder, Allen, and Passik (2012),
risk assessment stratification has become an important component in prescribing opioids
to patients with complaints of pain. From November 2016-April 2017, the clinic’s
providers have prescribed 457 active opioid prescriptions (S. Cole, personal
communication, May 8, 2017). Active refers to medications that are still being actively
dispensed to the patient currently and have not been discontinued. According to Hahn
(2011), the use of prescription opioid medications has the potential to lead to opioid
misuse, abuse, addiction, and diversion. Without providers assessing for the risk of
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misuse and abuse of opioids for these patients the risk of opioids versus the potential
benefits cannot be assessed.
The information collected through using the ORAST will allow each primary care
provider to individualize each patient’s plan of care to include whether the benefits
outweigh the potential risks of initiating opioid medications, as well as determine the
intensity of adherence monitoring if the provider chooses to move forward with initiating
opioid medication therapies. Opioid medication adherence monitoring includes follow-up
visits and assessment, urine toxicology screening, pill counts, and checking the
Prescription Monitoring Program’s database. According to Walghmare, Lelito, Detscher,
and Salcedo (2017), out of all patients prescribed opioid medications 50% of them do not
take their opioid medications as prescribed, this in turn, inflates health costs. The cost of
prescription opioid misuse and abuse represents a substantial economic burden for the
United States. According to Birnbaum, White, Schiller, Waldman, Cleveland, and Roland
(2011), the United States societal costs of prescription drug misuse and abuse totaled
$55.7 billon in 2007. In 2007, 12.5 million Americans utilized pain relievers for nonmedical purposes (Birnbaum et al., 2011).
Role of the DNP Student
I have dedicated my career as a nurse practitioner to serve patients with both acute
and chronic pain complaints. My passion and motivation for this doctoral project is to
improve the quality of life of the community and society. According to the American
Association of Colleges of Nursing (2006), the DNP graduate prepared for an Advanced
Practice Nursing role make improvements in the care of their particular patient
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population through utilization of a holistic perspective and use of diverse evidence-based
interventions. According to McCarbera, Nicolson, Todd, Palmer, and Penles, (2008),
untreated pain negatively impacts psychological, physical, and economical components
of every day life. For example, back pain alone accounted for $85-$100 billion in
healthcare expenditures in 2004 and 2005 (Jones et al., 2012). Pain, when not effectively
treated and/or relieved has a detrimental affect on all aspects of quality of life (Katz,
2002). Through utilization of a holistic, nursing approach that encompasses a variety of
non-opioid pain management modalities I am able to manage patients with complaints of
pain, improve their quality of life, and utilize opioids as a last line of treatment only after
calculating the benefits versus the risks.
My professional role in this doctoral project as a Family Nurse Practitioner who
specializes in pain management was to serve as the team leader, to review the evidence,
and present the evidence to the identified group of stakeholders in order to determine the
best ORAST for the ambulatory clinic’s population to recommend a practice change.
There are no other pain management specialists within the clinic. The ultimate goal of
this project is to setup the framework to have 100% of the ambulatory clinic’s primary
care providers utilize the selected ORAST prior to initiating opioid treatment. This will
allow for risk for aberrant behavior to be identified and treatment plans to be
individualized in order to improve patient safety and quality of care provided to reduce
opioid misuse, abuse, dependence, addiction, exposure, and overdose. Additionally, I
served as a pain management expert to the ambulatory care clinic. A potential bias I may
possess may include that I am practice as a pain management specialist within the same
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geographical location at the ambulatory care clinic. My passion for this specialty of pain
management may also pose as a potential bias. Steps to address these potential biases
included my being aware of them and seeking feedback from stakeholders.
This DNP project has the potential to assist primary care providers in identifying
the potential risk of misuse and/or abuse of opioids prior to initiating opioid management
for patients with complaints of pain through utilization of an ORAST. This will allow
primary care providers to be able to calculate the risk of misuse and/or abuse of opioids
for each patient with complaints of pain in order to customize a plan of care, which may
include deferring to prescribe opioids, or choose to prescribe with more intensified
adherence monitoring.
Role of the Project Team
The doctoral project team includes the stakeholders that have been identified for
the doctoral project. The stakeholders that have been selected for the purpose of the DNP
quality improvement project are the medical director and one resident from each of the
primary care teams. The medical director’s role within the clinic in addition to patient
care is overseeing the day-to-day operations to include facilitating policy changes based
on evidence-based practice guidelines. Additionally, he serves as an attending for the
residents, which includes supervising, teaching, and training them. It is important to
include the medical director, as he will oversee that the selected ORAST and policy
guiding provider use is being followed after graduation. The medical director supports
this doctoral project as he recognizes the need for an ORAST to be selected and
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implemented within the clinic, as there are a large number of patients being managed for
pain without application of the guidelines.
This inner-city ambulatory clinic divides its primary care patients amongst 10
resident-based teams; each team has between three and four residents. One resident from
each team was chosen to participate by the medical director. Stakeholder criteria for this
selection included availability to attend all meetings, provide feedback on the ORAST
and the developed policy guiding its use, and willingness to serve as a positive social
change agent within the clinic. It was important to have one primary care physician from
each team so there is cohesive involvement and representation from each team within the
clinic as they will be end-users of the selected ORAST in order to make a comprehensive
risk assessment of potential misuse and/or abuse prior to initiating opioids.
Implementation of the selected ORAST and policy guiding provider use will not be
completed until after graduation. At that time the resident doctoral team members will be
responsible for educating the other residents in each of their primary care teams.
According to White, Dudley-Brown, and Terhaar (2016), a microsystem approach
engages clinicians who provide direct care in order to improve the probability of
translation of evidence into practice. Ultimately failing to include a representative from
each team could later translate into failed acceptance of the selected ORAST and the
defined policy.
The strategy utilized to obtain the evidence needed to complete this doctoral
project included completing an integrated literature review and critically appraising the
strength of evidence to recommend an ORAST to clinic providers. The recommended
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ORAST was presented to the team. Together with the team a policy was developed based
on the needs of the clinic. The ORAST and policy to guide provider use was then
presented to and evaluated by the team using the AGREE II Instrument. Team members
were then asked to provide a summative evaluation of the DNP student learning
leadership within the project. The medical director will be the end decision maker as to
whether the selected ORAST and policy developed will be implemented. Implementation
of the ORAST and the policy guiding provider use will not be completed until after
graduation.
Summary
The practice problem in this DNP project was that providers failed to consistently
assess patients with complaints of pain for risk of opioid misuse and/or abuse prior to
initiating opioid medication. The sources of evidence and the analysis and synthesis of
this doctoral project will now be depicted.
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Section 3: Collection and Analysis of Evidence
Introduction
The practice problem in this DNP project was that providers failed to consistently
assess patients with complaints of pain for risk of opioid misuse and/or abuse prior to
initiating opioid medication. Individuals with co-occurring substance use disorders and/or
mental illness with complaints of chronic pain are at a higher risk for opioid misuse and
abuse (Sehgal, Manchikanti, & Smith, 2012). This clinic serves a patient population that
is known to have a history of aberrant behaviors, physical and/or sexual abuse,
psychological illness, and/or a family history of substance abuse (S. Cole, personal
communication, April 21, 2017). Of the 3,000 patients that the clinic serves
approximately 30% of those them are prescribed opioids for chronic, noncancer related
pain complaints (S. Cole, personal communication May 19. 2017). The patient
demographic for this clinic includes patients who have low health literacy levels, are of
low socioeconomic status, are insured by Medicaid and/or Medicare, have a history of
psychological illness, have complaints of chronic pain, have history a of substance abuse
disorders, and have a familial history of substance abuse (S. Cole, personal
communication May 19, 2017). Such patient populations have the potential to be at high
risk for opioid misuse and abuse.
Section 3 of this DNP project will depict the practice-focused question, the
sources of evidence, as well as analysis and synthesis of the evidence.
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Practice – Focused Question
The practice problem in this DNP project was that providers failed to consistently
assess patients with complaints of pain for risk of opioid misuse and/or abuse prior to
initiating opioid medication. The practice-focused question was as follows: “Will the
introduction of an opioid risk-assessment screening tool and the policy to guide provider
use help in identifying patients at risk for opioid misuse and/or abuse?”
The purpose of this Doctor of Nursing Practice project was to identify and
introduce an ORAST and then develop a policy to guide providers in its use in an
ambulatory care clinic. Currently, providers within the inner-city, ambulatory care clinic,
in the northeast of the United States continue to prescribe opioids without first
completing a comprehensive opioid risk-assessment on patients with complaints of pain.
This is most likely attributed providers lacking knowledge of the evidence-based practice
guidelines regarding safe opioid prescribing. According to Chou, Fanciullo, Fine,
Miaskowski, Passik, and Russel (2009), predicting the risk of aberrant opioid drugrelated behaviors through utilization of an ORAST may help providers develop an opioid
treatment plan to include deterring prescribing opioid medications for a patient at high
risk for abuse and/or misuse and the amount of rigidity needed to monitor for treatment
adherence if opioids are initiated.
Sources of Evidence
The sources of evidence used to address the practice-focused question were the
PubMed, Ovid, Medline and the CDC databases. The following keywords were used:
addiction assessment tool and compliance, predicting aberrant behavior and opioids, and
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opioid prescribing. I used Boolean operators AND and OR to optimize the results. The
scope of the review included literature sources between 2006 and 2017 as well as primary
resources prior to 2010. The strategy utilized to obtain the evidence needed to complete
this doctoral project included completing an integrated literature review and critically
appraising the strength of evidence to recommend an ORAST to clinic providers. The
recommended ORAST was presented to the team. Together with the team a policy was
developed based on the needs of the clinic. The ORAST and policy to guide provider use
was then presented to and evaluated by the team using the AGREE II Instrument. Team
members were then asked to provide a summative evaluation of the DNP student learning
leadership within the project.
Systematic Review of the Literature
According to Chou et al. (2009), ORAST can assist in developing an opioid
treatment plan that minimizes the risk of long-term opioid dependence and other
substance use problems. Additionally, risk stratification can assist in determining the
amount of opioid treatment structure in order to monitor the progress of opioid therapy
such as opioid agreements and frequency of urine toxicology testing. Opioid riskassessment screening tools measure potential risk of opioid misuse and abuse through
several factors to include history of aberrant behaviors, physical and/or sexual abuse,
psychological illnesses, or a family history of substance abuse as the presence of these
factors in a patient’s life may increase their risk of opioid misuse and abuse (Passik,
2008). According to Passik (2008), prior to prescribing opioids a patient’s risk of
developing an addiction should be assessed in order for opioid therapy to be effective and
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for the provider to be able incorporate this information in an opioid treatment plan.
According to Chou et al. (2009), all patients being considered for chronic opioid therapy
should be first screened for potential risk of substance misuse and abuse. It is important
to consider that every ORAST will not meet the individualized needs of each practice.
Selecting Opioid Risk-Assessment Screening Tool
Selecting an ORAST that is specific to the practice setting and patient
demographic is imperative. Factors to consider when selecting an ORAST for a specific
practice setting are: how the tool will be administered, the ease of scoring, the amount of
time it takes to administer and score, if the tool was validated, and the sensitivity and
specificity of the tool. According to Chou et al. (2009), using a validated assessment tool
conforms to the standard of care in opioid prescribing, as it is more accurate in the
information it provides to the prescribing provider. Patients that have a history of aberrant
behaviors, physical and/or sexual abuse, psychological illnesses, or a family history of
substance abuse may increase their risk of opioid misuse and/or abuse (Passik, 2008).
Choosing an ORAST that assesses for the presence of these factors would also be
important in order to make sure that the calculated risk stratification was accurate.
Finally, it is important to consider when the ORAST will be utilized. Certain tools are
validated for use prior to initiation of prescription opioid medication while others assist in
monitoring for adherence after prescription opioid medication has been initiated. For the
purpose of this doctoral project I focused on opioid risk-assessment screening tools that
can be utilized prior to initiating opioid medications.
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Validation, Sensitivity, and Specificity of Opioid Risk Assessment Screening Tools
Choosing an ORAST that has been both validated and has high sensitivity and
specificity is essential in order to ensure that information obtained from the ORAST is
accurate and can be relied obtain by the prescribing provider. Passik, Kenneth, Kirsch,
and Casper (2008), completed a comprehensive literature review in the Pubmed database
in 2016 using the search terms opioid and screening or assessment with or without the
additional terms risk and opioid-related disorders/prevention and control in order to
review and critique various opioid risk-assessment screening tools available to pain
clinicians for assessment of opioid misuse and abuse in patients with chronic, noncancer
pain. 43 publications were selected to review. According to Passik, Kenneth, Kirsch, and
Casper (2008), 19 of the 43 publications were rejected because the specific tool was not
adequately described. The study concluded that there are a variety of patient administered
and provider administered opioid risk-assessment screening tools, however not all of
them have been validated for use in patients with chronic pain. This is important as
failing to use a tool that is validated within the specific population that it will be used in
may change the reliability of the tool. Using a tool that is not validated within a specific
population may not adequately identify a patient that is at risk for opioid misuse and/or
abuse. According Passik, Kenneth, Kirsch, and Casper (2008), the tools that maybe
viable for assessing opioid abuse risk potential prior to initiating opioids are the Screener
and Opioid Assessment for Patients with Pain (SOAPP), The Diagnosis, Intractability,
Risk, Efficiency (DIRE), and the Opioid Risk Tool (ORT). Each tool has been validated
as an opioid risk-assessment screening tools for patients with complaints of pain.
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Additionally, clinicians should recognize the psychometric and other features of each
ORAST in order to select the ORAST that best suits their patient population. In other
words, the ability of the ORAST to account for history of sexual abuse or psychological
illness is important as those factor may increase the potential risk of a person to misuse
and/or abuse opioid medications. The strengths of the study completed by Passik et al.
(2008), include the study design, as it is a comprehensive meta-analysis literature review.
The limitations of the study include that no prospective criteria was used to assess the
strength of the study design, and article selection was subjective in nature.
Selecting an ORAST that is validated for the patient population it will be utilized
within, as well as selecting an ORAST that is of high sensitivity and specificity is
important; an ORAST is more reliable if it has higher probability of obtaining accurate
information through screening. Butler. Fernandez, Benoit, Budman, and Jamison (2008),
completed a prospective study with the purpose of validating an empirically derived
version of the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPPR) that addresses some limitations of the Screener and Opioid Assessment for Patients
with Pain (SOAPP). 85 patients were recruited from an urban-based pain clinic in the
Boston area. All participants were in treatment for chronic noncancer related pain and on
a long-term opioid treatment. The participants completed a beta version of the SOAPP-R.
At follow-up, a researcher conducted a semi-structured interview and collected urine
specimens. The study concluded that the SOAPP-R had adequate sensitivity (.81) and
specificity (0.68) in predicting risk potential for aberrant behavior, which is in
improvement from the SOAPP. Additionally, the study summarized that the SOAPP-R
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has the potential to provide clinicians with the ability to be more aware of patients who
are at risk for aberrant behaviors and may require more stringent adherence monitoring.
The limitations of this study include the sampling was of convenience. Additionally,
patients included in the study were already on opioid medications. A strength of the study
was that of the participants that volunteered to participate, a randomly selected group was
asked to complete the beta version of the SOAPP-R to determine retest-reliability.
Jones, Moore, Levy, Daffron, Browder, Allen, and Passik (2012), completed two
studies on opioid risk-assessment screening tools. The first was a comparative study with
the purpose of comparing different opioid risk-assessment screening tools and their
ability to predict patient discharge from opioid treatment within a pain clinic. A sample
of 132 patients who were patients within a pain clinic in Knoxville Tennessee
participated. Patients were 18 years of age or older, and had their opioid prescription
medications discontinued due to aberrant behavior. Between February 2008 and February
2009 each of the participants completed four different opioid risk-assessment screening
tools that included, a clinic interview with a psychologist, the SOAPP-R, the PMQ, and
the ORT. The study concluded that the risk rating of a clinical psychologist was the most
sensitive predictor of discharge (43%). The SOAPP-R identified 32% of patients
discharged, PMQ 22%, and the ORT 10%. The limitations of this study include, only the
measure of sensitivity was assessed for which comprises one-half of the clinical picture
as specificity was not measured. Additionally, all participants were already discontinued
from opioid management due to aberrant behaviors. The strengths of the study included
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that it identified the importance of selecting opioid risk assessment-screening tools based
on both sensitivity and specificity.
The second study that was completed by Jones, Moore, Levy, Daffron, Browder,
Allen, and Passik (2012), was a prospective study that collected data amongst patients
who presented to a psychologist located in a pain practice in Knoxville, Tennessee
between September 2007 and May 2008. All patients were referred by pain consultants in
Tennessee for risk assessment prior to initiation of opioids for chronic pain. Opioid riskassessment screening tools included a semi- structured clinical interview, the SOAPP-R,
the ORT, and the PMQ. The study concluded the sensitivity and specificity of each
ORAST had the following sensitivity and specificity in regards to predicting aberrant
behavior. The ORT had 17.6% sensitivity and 88.1 % specificity; the PMQ had 35.8%
sensitivity and 78.1% specificity; the SOAPP-R had 41.4% sensitivity and 71.0%
specificity; Psychologist One had 69.2% sensitivity and 62.2% specificity; and
Psychologist Two had 16.7% sensitivity and 83.3% specificity. One strength of the study
was the participants were reflective of the population of the region. An additional
strength of the study was that six months after the initial opioid risk-assessment
screenings were completed, information was gathered about each patient’s treatment plan
and status to verify accuracy of each opioid risk-assessment screening tools ability to
predict risk for aberrant behavior.
Belgrade, Schamber, and Lindgren (2006), completed a retrospective study to test
the validity and reliability the DIRE tool. DIRE scores were assigned to 61 cases from a
pain center’s database. The cases were then abstracted into vignettes that were reviewed
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and scored by six physicians. Repeat scoring was then completed for 30 additional
vignettes two weeks later. The study concluded that the internal consistency of the DIRE
tool was high (Cronbach’s alpha = .80); sensitivity was 94% and specificity was 87%
with an intra class correlation of 0.94 and an interrater reliability of 0.95. Finally, it was
concluded the implementing the DIRE tool would take providers 102 seconds to carry out
and score. A limitation of the study was its design as it was retrospective. A strength of
the study was the physicians completing the DIRE assessment of the vignettes were all
primary care providers.
Barriers to Implementing an Opioid Risk-Assessment Tool
Recently, the use of opioid medications for noncancer related pain have been
associated with a heightened stigma as there has been an increase in opioid misuse,
abuse, dependence, addiction, and deaths. According to Belgrade, Scamber, and Lindgren
(2006), providers that treat patients with chronic, noncancer related pain need to be
strategic in determining which patients would be most compliant with the opioid
prescribing process as well as what patients would benefit from opioid management.
According to Shapiro, Coffa, and McCance-Katz (2013), more than 20% percent of
primary care providers described themselves as ill prepared to identify substance abuse
within their outpatient populations. According to Passik, Kirsh, and Casper (2008), the
use of an ORAST allows individual patients to be screened for risk of opioid misuse
and/or abuse so their risk stratification can be incorporated in their treatment plan by their
providers. The following barriers to utilizing an ORAST prior to initiating opioid
management have been identified.
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•

Until recently, few tools were validated for assessment of opioid related
risks for patients with complaints of pain being considered for opioid
management (Passik, Kirsh, & Casper, 2008).

•

Many clinicians struggle to find an ORAST that they can incorporate into
their practice setting and medical record keeping (Passik, Kirsh, & Casper,
2008).

•

There is a lack of training in substance abuse amongst primary care
providers (Hahn, 2011).

•

Providers are often unsure which ORAST is most appropriate for their
patient population and screening needs (Passik, Kirsh, & Casper, 2008).

•

Not all opioid risk-assessment screening tools have been validated to be
used to assess for misuse and/or abuse potential in patients prior to
initiating opioid therapies (Passik, Kirsh, & Casper, 2008).

The providers in an inner-city ambulatory care do not consistently assess
for potential risk of opioid misuse and abuse prior to initiating prescription opioids
medications to patients with complaints of pain. The providers within the clinic are faced
with many barriers in selecting and implementing an ORAST in their practice setting.
Many of the providers have little to no training in pain management. Additionally, there
is a knowledge deficit amongst providers within the clinic in regards to the opioid riskassessment screening tools that are available and what the benefits and limitations are of
each ORAST. Ultimately, the providers within the clinic are looking for an ORAST that
is validated in patients with complaints of pain, has a high degree of sensitivity and
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specificity, can be self administered by the patient, it easy to administer and score,
identifies co-existing substance abuse and mental illness conditions and would take less
than two minutes to administer and score so it does not impede workflow.
In completing a comprehensive literature review, I was able to select an ORAST
that would best suit the needs of their clinic. The recommended ORAST was presented to
the team. Together with the team a policy was developed based on the needs of the clinic.
The ORAST and policy to guide provider use was then presented to and evaluated by the
team using the AGREE II Instrument. Team members were then asked to provide a
summative evaluation of the DNP student learning leadership within the project.
Opioid Risk-Assessment Screening Tools
Four opioid risk-assessment screening tools were analyzed for the purpose of this
doctoral nursing project were The Opioid Risk Tool (ORT), The Screening Instrument
for Substance Abuse Potential (SISAP), The Screener and Opioid Assessment for
Patients with Pain – Revised (SOAPP-R), and the Diagnosis, Intractability, Risk,
Efficacy (DIRE). These opioid risk-assessment screening tools were analyzed because
they were the only validated opioid risk-assessment screening tools recommended for use
prior to initiating opioid management in an outpatient setting. Opioid risk-assessment
screening tools that were validated to be used after opioid management is initiated by
were excluded. Evidence-based practice guidelines recommend patients with complaints
of pain to be screened for potential opioid misuse and/or abuse prior to initiating
prescription opioid medications (Passik, Kirsh, & Casper, 2008). Benefits and limitations
of each ORAST were analyzed in terms of sensitivity, sensitivity, reliability application
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to the practice setting and population, psychometrics of the tool, and the time to
administer and score.
Opioid Risk Tool
The Opioid Risk Tool (ORT) provides excellent discrimination between high risk
and low risk of aberrant behaviors in patients prior to them being prescribed opioid
medications (Passik, 2008). The ORT consists of five items, which include family history
of substance abuse, personal history of substance abuse, age, history of preadolescent
sexual abuse, and psychological abuse. Scoring for males is separated from females. A
cumulative score of three or lower indicated low risk for future opioid risk, while a score
of four to seven indicates moderate risk, and a score of eight or higher indicates high risk.
This is a patient administered tool, intended for a primary care setting, and takes less that
one minute to administer and score. The ORT has “exhibited a high degree of sensitivity
and specificity for determining which individuals are at a high risk for opioid abuse”
(Webster & Webster, 2005).
Advantages. The advantages of the ORT are as follows.
•

The ORT utilizes brief and simple scoring that is validated in pain populations
(Passik et al, 2008).

•

The ORT is developed specifically for pain patients (Butler, 2008).

•

Providers excellent discrimination from patients at low risk versus high risk
(Passik et al., 2008).

•

The ORT takes less than one minute to administer and score.

•

Identifies co-existing mental health conditions.
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•

Identifies co-existing substance abuse conditions.

•

Scoring is gender specific.

Limitations. The limitations of the ORT are as follows.
•

The question regarding family history of substance abuse is dependent on the
patient’s knowledge of family history of substance abuse (Passik et al., 2008).

•

The ORT is a self-reporting tool. Therefore scoring is dependent on the
patient’s degree of honesty.

The Screening Instrument for Substance Abuse Potential
According to Coambs, Larry, Santhiapillai, Abrahamsohn, and Atance (1996), the
Screening Instrument for Substance Abuse Potential (SISAP) is an ORAST to assess
patients with a substance abuse history as well as a high risk for opioid abuse and/or
dependency. The SISAP has a good specificity, a good sensitivity, high correct
classification rate, and a low incidence rate of misses (Coambs et al., 1996). The tool is
based on five items, takes less than one minute to administer and score, is administered
by means of interviewing the patient, and is intended for a primary care setting. The
SISAP questions include:
1. If you drink alcohol, how many drinks do you drink on a typical day?
2. How many drinks do you have in a typical week?
3. Have you used marijuana or hashish in the past year?
4. Have you ever smoked cigarettes?
5. What is your age?
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Based on the scoring of the SISAP, it is recommended that caution be used when
prescribing opioids to patients who meet the following criterion.
• Men who drink more than four alcoholic beverages per day or 16 per week.
• Woman who drink more than three alcoholic beverages per day or 12 per week.
• Persons who admit to recreational use of marijuana or hashish in the previous
year.
• Persons whom are younger than 40 years of age and smoke.
Advantages. The advantages of the SISAP are as follows.
• The SISAP has been found to have a high sensitivity and specificity in assisting
primary care providers in determining if a patient receiving opioids is at risk for
opioid misuse and/or abuse (Passik, Kirsh, & Casper, 2008).
• The SISAP was developed specifically for primary care providers to use within
their clinical practice (Passik, Kirsh, & Casper, 2008).
• The SISAP differentiates between alcohol and drug risk (Butler, 2008).
• The SISAP takes less than one minute to administer and score.
Limitations. The limitations of the SISAP are as follows.
• The SISAP has not been validated in pain patients (Passik et al., 2008).
• The SISAP does not identify co-existing mental health conditions.
The Screener and Opioid Assessment for Patients with Pain – Revised
According to Butler et al. (2008), the Screener and Opioid Assessment for
Patients with Pain – Revised (SOAPP- R) is an ORAST that predicts the possibility of
opioid misuse and/or abuse in patients with complaints of chronic pain. The SOAPP-R
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consists of 24 items that respondents can answer (0) –Never, (1) – Seldom, (2) –
Sometimes, (3) – Often, and (4) Very Often. A provider scores the SOAPP-R by
calculating the cumulative scores of questions 2, 7, 10, 11, 12, 13, 15, 17, 18,19, 20, 23,
and 24. A cumulative score of seven or higher indicates the patient is high risk for opioid
misuse and/or abuse. The SOAPP-R takes approximately five minutes to administer and
score, is intended for a primary care setting, and is administered by means of a selfreporting questionnaire. According to Passik et al. (2008), the SOAPP-R is excellent in
deciphering the difference between high risk and low risk patients.
1. How often do you have mood swings?
2. How often have you felt a need for higher doses of medication to treat your
pain?
3. How often have you felt impatient with your doctors?
4. How often have you felt that things are just too overwhelming that you cannot
handle them?
5. How often is there tension in the home?
6. How often have you counted pain pills to see how many are remaining?
7. How often have you been concerned that people will judge you for taking pain
medication?
8. How often do you feel bored?
9. How often have you taken more pain medication than you were supposed to?
10. How often have you been worried about being left alone?
11. How often have you felt a craving for medication?
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12. How often have others expressed concern over your use of medication?
13. How often have any of your close friends had a problem with alcohol or
drugs?
14. How often have others told you that you had a bad temper?
15. How often have you felt consumed by the need to get pain medication?
16. How often have you run out of pain medication early?
17. How often have others kept you from getting what you deserve?
18. How often, in your lifetime have you had legal problems or been arrested?
19. How often have you attended an AA or NA meeting?
20. How often have you been in an argument that was so out of control that
someone got hurt?
21. How often have you been sexually abused?
22. How often have others suggested that you have a drug or alcohol problem?
23. How often have you had to borrow pain medications from your family or
friends?
24. How often have you been treated for an alcohol or drug problem?
Advantages. The advantages of the SOAPP-R are as follows.
• The SOAPP-R is easily understood by patients (Butler et al., 2008).
• The SOAPP-R was developed specifically for patients with complaints of pain.
• The SOAPP-R is less susceptible for patient deception in comparison to the
original SOAPP.
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• Best psychometrics of any measure designed to predict aberrant behavior before
opioid therapy is begun (Passik et al., 2008).
Limitations. The limitations of the SOAPP-R are as follows.
• The SOAPP-R is less sensitive and less specific to the original SOAPP (Butler et
al., 2008).
• Briefer tools than the SOAPP-R may be preferred by providers (Passik et al.,
2008).
• The SOAPP-R has 24 items and takes five minutes to administer and score.
• The SOAPP-R is a self-reporting tool. Therefore scoring is dependent on the
patient’s degree of honesty.
The Diagnosis, Intractability, Risk, Efficacy
The Diagnosis, Intractability, Risk, Efficacy (DIRE) is an ORAST for patients
that are potential candidates for long-term opioid management. This tool intended for
primary care settings and is comprised of seven items, which are collected by means of a
patient interview. It takes less than two minutes to administer and score. According to
Passik et al. (2008), the DIRE has been validated by six experts studying patient case
vignettes. Additionally, the DIRE has been found to have high internal consistency,
sensitivity, efficacy, and specificity (Belgrade, Schamber, Lindgren, 2006). The factors
that are included in the DIRE scoring include: diagnosis, intractability, psychological,
chemical health, reliability, social support, and efficacy score. A score of seven through
thirteen is interpreted, as the patient may not be a suitable candidate for long-term
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analgesics. A score of 14 through 21 suggests that the patient may be a candidate for
long-term analgesics.
Advantages. The advantages of the DIRE are as follows.
• The DIRE has been specifically designed for primary care use (Passik et al.,
2008).
• A patient’s DIRE score correlates well with patient compliance and efficacy of
long-term opioid treatment (Belgrade, Schamber, Lindgren, 2006).
• The DIRE has been found to be a rapid assessment tool that is both valid and
reliable in selecting patients for long-term opioid analgesic management
(Belgrade, Schamber, Lindgren, 2006).
• The DIRE takes less than two minutes to administer and score.
Limitations. The limitations of the DIRE are as follows.
• Prospective validation is needed (Passik et al., 2008).
Recommended Guidelines for the Treatment of Chronic Pain
According to the CDC (2016) recommended guidelines for the treatment of
chronic pain include:
•

Use non-opioid therapies to the extend possible.

•

Assess risk and address harms of opioid use and when to initiate opioid
medications.

•

Identify and address co-existing mental health conditions.

•

Focus on functional goals and improving, engaging patients actively in their
pain management.
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•

Use disease-specific treatments when available.

•

Use first-line medication options preferably.

•

Consider interventional therapies in patients who fail standard non-invasive
therapies.

•

Use multimodal approaches, including interdisciplinary rehabilitation for
patients who have failed standard treatments, have severe functional deficits,
or psychological risk factors.

The purpose of the recommended guidelines to treat chronic pain is to limit
prescription opioid misuse, abuse, addiction, dependence, and exposure (CDC, 2017).
Using alternative treatment modalities for pain and reserving opioid medications for
when other treatment options fail is the best approach to pain management (CDC, 2017).
Prior to initiating opioid medications an opioid risk-assessment should be completed to
assess for the risk of opioid misuse and abuse. Selecting an ORAST that meets the
specific needs of the clinic is imperative in order to make positive social change.
According to Sehgal, Manchikanti, and Smith (2012), individuals with complaints of
chronic pain and co-occurring substance abuse disorders, and/or mental illness are at a
higher risk for opioid misuse and abuse. This clinic serves a patient population that is
known to have a history of aberrant behaviors, physical and/or sexual abuse,
psychological illness, and/or a family history of substance abuse (S. Cole, personal
communication, April 21,2017). The providers within the clinic need an ORAST that is
validated in patients with complaints of pain, has a high degree of sensitivity and
specificity, can be self administered by the patient versus provider administered, is easy
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for patients to comprehend, is simple for providers to score, identifies co-existing
substance abuse and mental illness conditions and would take less than two minutes to
administer and score so it does not impede workflow.
Recommending an Opioid Risk-Assessment Screening Tool
The purpose of this DNP project was to identify and introduce an ORAST and
then develop a policy to guide providers in its use in an ambulatory care clinic. Currently,
providers within the inner-city, ambulatory care clinic, in the northeast of the United
States continue to prescribe opioids without first completing a comprehensive opioid
risk-assessment on patients with complaints of pain.
The providers within the clinic need an ORAST that is validated in patients with
complaints of pain and has a high degree or sensitivity and specificity (S. Cole, personal
communication May 19, 2017). According to Passik, Kirsh, and Casper (2008), until
recently few opioid risk-assessment screening tools were validated for opioid related
risks for patients being considered for opioid management. Failing to use an ORAST that
is validated or does not have a high degree of sensitivity and specificity can calculate
potentially inaccurate results. Additionally, the clinic needs an ORAST that can
completed by the patient, is easily scored by the provider and would take less than two
minutes to administer and score so it does not impede workflow (S. Cole, personal
communication May 19, 2017). According to Passik, Kirsch, and Casper (2008), finding
an ORAST that can be incorporated into a practice setting is a struggle for many
clinicians. With limited resources, to include limited staffing, it was important to find an
ORAST that would not disrupt workflow otherwise there may be an increased potential
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for decreased adherence amongst providers using the selected ORAST and the policy
formulated to guide its use. Finally, this inner-ambulatory clinic has a serves a patient
population that is known to have co-occurring substance use disorders and mental illness
(S. Cole, personal communication May 19, 2017). Therefore it is important for the
selected ORAST to identify co-existing substance abuse and mental illness conditions.
According to Sehgal, Manchikanti, and Smith (2012), individuals with complaints of pain
and have co-occuring substance use disorders and/or mental illness are at a higher risk for
opioid misuse and abuse. Failing to have an ORAST that appropriately screens the
specific patient demographic of this inner-city ambulatory clinic for the potential risk of
opioid misuse and abuse may not allow for providers to accurately determine the
potential risk for opioid misuse and abuse. Ultimately this may put the patient at
increased risk if the provider prescribes a patient opioids without factoring in the impact
of either co-occuring substance abuse disorders or mental illness on the patient’s potential
risk for opioid misuse and abuse. Based on the needs of the clinic the following inclusion
and exclusion criteria were identified for an ORAST.
Inclusion Criteria
• Can be utilized prior to initiating prescription opioid medications
• Is validated in patients with complaints of pain
• Has a high degree of sensitivity and specificity
• Can be self administered by the patient
• Can be easily scored by the provider
• Take less than two minutes to administer and score
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• Identifies co-existing substance abuse and mental illness conditions
Exclusion Criteria
• Can not be utilized prior to initiating prescription opioid medications
• Is not validated in patients with complaints of pain
• Does not have a high degree of sensitivity and specificity
• Cannot be self administered by the patient
• Cannot be easily scored by the provider
• Take greater than two minutes to administer and score
• Does not identify co-existing substance abuse and mental illness conditions
Eliminated opioid risk-assessment screening tools. After critically reviewing
and appraising the literature, and the inclusion and exclusion criteria of an ORAST based
on the needs of the clinic, it was determined that the SISAP, DIRE, and SOAPP-R would
not be the best fit for the clinic or meet the providers’ needs. The SOAPP-R was
eliminated, as it is a 24-item tool, requiring five minutes to be completed by the patient
and scored by the provider. This would be time consuming, potentially hinder workflow,
and be less likely to be successfully implemented into practice. Additionally, it has been
found to be less specific and have less sensitivity then the original SOAPP (Passik et al.,
2008). The DIRE was eliminated as it lacked prospective validation (Passik et al., 2008).
Failing to use a validated tool may not allow for accurate information to be obtained.
Providers need to be assured that they can rely on the information obtained from the
selected ORAST so they can feel confident in the individualized plan of care they are
developing specific to prescription opioid medications. The SISAP was eliminated
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because it does not assess for co-existing mental health conditions. This inner-city clinic
serves a large mental health patient population. Additionally, mental health illnesses have
been found to increase the potential risk of opioid misuse and/or abuse (Passik et al.,
2008). Finally, the SISAP was not validated in patients with complaints of pain.
Opioid risk-assessment screening tool to be recommended. The Opioid Risk
Tool (ORT) is the most appropriate ORAST for this ambulatory outpatient clinic because
it will meet the needs of the clinic and provides an assessment that will meet the
recommendation from the CDC (.2016). My recommendation of selecting the ORT was
presented to the DNP project team for their review and input after IRB approval was
obtained. The ORT provides excellent discrimination between patients at high risk versus
low risk for opioid misuse and/or abuse prior to initiating opioids (Passik et al., 2008).
This clinic serves a patient population that is known to have a history of aberrant
behaviors, physical and/or sexual abuse, psychological illness, and/or family history of
substance abuse (S. Cole, personal communication, April 21,2017). The ORT consists of
five items, which include family history of substance abuse, personal history of substance
abuse, age, history of preadolescent sexual abuse, and psychological abuse. The ORT will
allow for patients that have history of psychological illness, physical or sexual abuse, and
substance abuse history to be appropriately screened for risk of opioid misuse and abuse.
Additionally, the ORT takes less than one minute to be completed by the patient and
scored by the provider, and has been validated in patients with complaints of pain (Passik
et al., 2008). The use of the ORT should not impede provider workflow, and may help to
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ensure the information collected from the ORT is accurate. As a result, the providers may
feel more confident in relying on the selected ORAST.
Ethical Considerations
Ethics approval was requested from the Walden Institutional Review Board (0804-17-0386824), which included the pre-approved site Agreement and the Disclosure to
Expert Panelist Form for Anonymous Questionnaires. Names of partner organizations
were changed, geographic location generalized, and data was not collected from patients
or patients’ family members. It was ensured that no proprietary, sensitive or confidential
information was disclosed in this doctoral project document, and all organization’s
policies were complied with. Based on the IRB requirements all data collected for this
DNP project, each team members anonymously completed AGREE II Instrument and
summative evaluation, will be stored in a locked cabinet for five years.
Analysis and Synthesis
This DNP project plan used a Plan-Do-Study-Act (PDSA) approach to complete
an integrated literature review on pain management with critical appraisal of the strength
of the evidence. An appropriate ORAST was identified as a part of the initial literature
review and was then recommended to the project team after obtaining Walden IRB and
site approval. The DNP project team consisted of the medical director and one resident
from each of the 10 primary care teams. The team was convened to study and analyze the
evidence from the literature on the four opioid risk-assessment screening tools based on
the inclusion and exclusion criteria that was previously identified. The project team then
developed a policy to guide the use of the selected ORAST within the clinic. Team
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members were then asked to complete the AGREE II Instrument and provide a
summative evaluation of the DNP student’s leadership in project planning and
implementation. Prior to making this request all team members were provided the
Disclosure to Expert Panelist Form for Anonymous Questionnaires (Appendix B), a
complete Opioid Risk Tool (Appendix A), and a detailed explanation of the AGREE II
Instrument.
Summary
Section 3 restated the problem and purpose for this DNP project, as well as
depicted the practice – focused question, sources of evidence, and the methodologies that
would be utilized to analysis and synthesize the data that will be obtained. Section 4 will
report the findings and implications of the data, describe proposed recommendations,
summarize the contribution of the Doctoral project team, and discuss the strengths and
weaknesses of the project.
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Section 4: Findings and Recommendations
The practice problem in this DNP project was that providers failed to consistently
assess patients with complaints of pain for risk of opioid misuse and/or abuse prior to
initiating opioid medication. The practice-focused question was as follows: “Will the
introduction of an opioid risk-assessment screening tool and the policy to guide provider
use help in identifying patients at risk for opioid misuse and/or abuse?”
The purpose of this DNP project was to identify and introduce an ORAST and
then develop a policy to guide providers in its use in an ambulatory care clinic. Currently,
providers within the inner-city, ambulatory care clinic, in the northeast of the United
States continue to prescribe opioids without first completing a comprehensive opioid
risk-assessment on patients with complaints of pain.
The sources of evidence used to address the practice-focused question were the
PubMed, Ovid, Medline and the CDC databases. The following keywords were used:
addiction assessment tool and compliance, predicting aberrant behavior and opioids, and
opioid prescribing. I used Boolean operators AND and OR to optimize the results. The
scope of the review included literature sources between 2006 and 2017 as well as primary
resources prior to 2010. The strategy utilized to obtain the evidence needed to complete
this doctoral project included completing an integrated literature review and critically
appraising the strength of evidence to recommend an ORAST to clinic providers. The
recommended ORAST was presented to the team. Together with the team a policy was
developed based on the needs of the clinic. The ORAST and policy to guide provider use
was then presented to and evaluated by the team using the AGREE II Instrument. Team
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members were then asked to provide a summative evaluation of the DNP student learning
leadership within the project.
Doctoral Project Team
The doctoral project team included the stakeholders that have been identified for
the doctoral project. The stakeholders that were selected for the purpose of this DNP
quality improvement project were the medical director and one resident from each of the
primary care teams. The medical director selected one resident from each of the 10
primary care teams. Stakeholder criteria for selection included availability to attend all
meetings, provide feedback on the selected ORAST and the developed policy guiding its
use, and the willingness to serve as a positive social change agent within the clinic. In
total there were 11 stakeholder team members. The residents were notified about this
doctoral project and requested to participate by the medical director. All 11 team
members participated by attending two round table discussions that were held in the
resident conference room. All 11 team members voted and completed an AGREE II
Instrument and summative evaluation.
Stakeholder Process and Policy Development
The stakeholder team included the medical direct and one resident from each of
the ten primary care teams (n =11). The residents were asked to participate by the
medical director. All 11 team members participated by attending two round table
discussions. During the first discussion my recommendations and the information
obtained from my comprehensive literature review, which included recommended
guidelines for opioid medications were presented to the stakeholder team to include a
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presentation of each of the four opioid risk-assessment screening tools. The stakeholder
team discussed the information presented to include what they felt the pros and cons were
of each ORAST and how ORAST would help or hinder their present practice. The
consensus of the team was the SOAPP-R was too long and would not be feasibly
implemented into their daily practice. Additionally, the DIRE did not make the team feel
like they could rely on the tool as it lacked prospective validation. In terms of the SISAP,
the team was concerned that it did not assess for co-existing mental health conditions
especially since a large percentage of their patient population has mental illness, and the
literature has suggested that mental illness can increase risk for opioid misuse and abuse.
Finally, the team consensus in regards to the ORT was it seemed to be the best fit for
their present patient population and workflow because it was quick to administer and
score, was accurate, and screened for mental illness. Thereafter, my recommendation of
the Opioid Risk Tool (ORT) as being the most appropriate ORAST for this clinic was
voted upon by all team members, and policy guiding the use of the ORT began to be
created with all 11 team members. Voting was done by simply going around the table and
having each member say “yes” they agreed or “no” they did not. There was no anonymity
in the voting process. This was identified as a limitation of the DNP project, which will
be later discussed.
Collaborating amongst team members to formulate the policy to guide the use of
the ORT was done in open dialogue using the domains of the AGREE II Instrument as
structure to guide the conversation and CDC guidelines to inform the policy structure. All
stakeholders spoke openly about their interpretation of the information presented as well
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their opinions, experiences, and perspectives interchangeable until a consensus was
reached on the policy to define the use of the ORT in the clinic. The medical director, as
part of the project team, participated fully in this process with the rest of the team
members. Given his role within the clinic he served as an expert in policy content. The
medical director’s interactions with the group appeared to be very supportive and not
authoritative. There did not appear to be any bias from the group due to his presence.
I took notes throughout the meeting as a means to document team communication
on points to be included in the policy. The notes revealed that the stakeholder team
wanted a policy that required the ORT to be utilized prior to initiating any/all opioid
medication amongst the residents for patients with complaints of pain. Additionally,
notes indicated that the stakeholder team wanted a policy that allowed for greater
learning opportunities regarding pain management than the clinic presently offered.
Overall the team felt that their knowledge about prescription opioid medications and pain
management was lacking and there was little opportunity to improve. The team believed
that a policy requiring the residents to discuss the plan of care with their attending would
facilitate an opportunity for them to develop their knowledge base on pain management
and prescribing opioid medications. Thirdly the stakeholder team liked how the ORT
scored patients as low, moderate, or high risk for opioid misuse and/or abuse but they did
not want a policy to dictate the care that was provided solely based on risk assessment.
Instead they wanted to be able to have a policy that allowed for the information obtained
from the ORT to be presented by residents to their attending so together a comprehensive
plan of care based on recommended guidelines could be created, documented, and
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implemented. Based on the stakeholder meeting, I composed a formal policy to
recommend to the team that would guide the use of the ORT (Appendix E).
During the second round table discussion the final policy based on the stakeholder
team’s input was presented to the all 11 members of the stakeholder team for the review
and feedback. All 11 team members were asked to anonymously complete the AGREE II
Instrument (Appendix C) and summative evaluation (Appendix D). Prior to this request
all team members were provided the Disclosure to Expert Panelist Form for Anonymous
Questionnaires (Appendix B), a complete Opioid Risk Tool (Appendix A), and detailed
explanation of the AGREE II Instrument. I then utilized simple descriptive statistics to
determine what percentage of the stakeholder team rated each of the domains in the
AGREE II Instrument (Table 1) and each of the items in the summative evaluation (Table
2). The stakeholders’ completed summative evaluation and the AGREE II Instrument
were kept anonymous and placed in an envelope after their completion. Evaluation of the
results did not take place until after the meeting. None of the team members filled out any
of the comment sections in the AGREE II Instrument. So in areas that were rated as
mostly agree or strongly agree on the AGREE II Instrument, or agree versus strongly
agree on the summative evaluation there was no ability for recommendations to be
reviewed and incorporated into further revisions. The medical director will be the end
decision maker as to whether the selected ORAST and policy developed will be
implemented in the clinic setting. Implementation of the selected ORAST and the policy
guiding provider use will not be completed until after graduation.
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Findings and Implications
The finding of this DNP project in regards to the results of the AGREE II
Instrument and summative evaluation will now be discussed. The implications of the
project results, including the potential for social change, the strengths and limitations of
the project, and future recommendations will be identified.
Appraisal of Guidelines Research and Evaluation (AGREE) II Instrument
According to Walden University (2017), the Appraisal of Guidelines Research
and Evaluation (AGREE) II Instrument provides the framework that can be utilized by
the DNP to develop clinical practice guidelines and to assess the quality of the guidelines
developed. Each member of the stakeholder team (n = 11) was asked to use the AGREE
II Instrument (Appendix C) to assess the quality of the evidence of the policy used to
formulate the recommendation. The According to the Agree Resource Trust (2013), the
AGREE II Instrument is comprised of 23 items which are organized into seven domains.
Additionally, there are two global rating items. The seven domains include:
• Scope and Purpose
• Stakeholder Involvement
• Rigor of Development
• Clarity of Presentation
• Applicability
• Editorial Independence
• Overall Guideline Assessment
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Scope and Practice assures that the overall objectives of the guidelines, the health
questions, and the population to whom the guideline is meant to apply to were
specifically described (AGREE, 2013). Stakeholder Involvement evaluates the
involvement of relevant professional groups in the development of the guideline, if the
views and preferences of the target population have been sought, and if the target users of
the guideline were are clearly defined (AGREE, 2013). Rigor of Development evaluates
the details presenting regarding the strategy used to search for evidence (AGREE, 2013).
This includes assessing if the methods for formulating the recommendations were clearly
described. Clarify of Presentation reflects the clear and concise description of the policy
(AGREE, 2013). Applicability accounts for the degree in which the guideline provides
advice on how the recommendation should be put into practice (AGREE, 2013). Finally,
Editorial Independence assures that the guidelines were not influenced by external
interests (AGREE, 2013). The Overall Guideline Assessment refers to the overall rated
quality of the guideline and recommendations for use (AGREE, 2013).
The AGREE II Instrument uses rates each of the domain on a seven-point scale as
1 = strongly disagree, 2 = moderately disagree, 3= disagree, 4 = neither agree nor
disagree, 5 = agree, 6 moderately agree, and 7 = strongly agree (Agree Resource Trust,
2013). All 11 team members were asked to complete the AGREE II Instrument
(Appendix C) and summative evaluation (Appendix D).
The results of the AGREE II Instrument are summarized in Table 1.
Implementation of the ORT and the policy to guide its use will occur after graduation.
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Table 1.
Results of AGREE II Instrument
Domain

Agree %

Moderately Agree % Strongly Agree %

1. Scope and practice

0

36

64

2. Stakeholder involvement

9

55

36

3. Rigor of development

0

45

55

4. Clarity of presentation

0

18

82

5. Applicability

0

18

82

6. Editorial independence

0

9

91

Overall the team agreed on the appropriateness of the components included in the
policy and procedure and supporting evidence, and expressed that they felt the policy
should be implemented into their practice setting. Simple descriptive statistics were
utilized to calculate what percentage of the group rated each domain on the seven-point
Likert scale. While 64% of the team members strongly agreed on Scope and Practice of
the policy and procedure, 36% responded moderately agree. 36% of the team responded
that they strongly-agreed on Stakeholder Involvement while 55% moderately agreed and
9% agreed. Thirdly, 35% of the team responded that they strongly-agreed on Rigor and
Development, while 45% moderately-agreed. In regards to Clarity and Presentation 82%
of the team responded that they strongly-agreed while 18% moderately-agreed. In terms
of Applicability 82% of the team responded that they strongly-agreed while 18%
moderately-agreed. Finally, 91% of the team strongly-agreed while 18% moderately-
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agreed on Editorial Independence. As none of the 11 participants wrote on comments on
the AGREE II Instrument that was collected, and responses were kept anonymous I was
unable to summarize the variability in rating amongst the team as none of the participants
commented on the AGREE II Instrument that was collected. This was seen as a limitation
of this doctoral project. Overall all 11 team members scored all domains within the
AGREE II Instrument as either Strongly Agree or Moderately Agree. This concludes that
the proposed policy developed with the team guiding the residents’ use of the ORT can
be recommended for use in practice
Summative Evaluation of DNP
The DNP project team also completed a summative evaluation. The summative
evaluation was comprised of 11 items. Each of the 11 items was rated on a five-point
scale where five was strongly agree to one-strongly disagree by each of the DNP project
team members. The results of the summative evaluation are summarized in Table 2.
Table 2.
Results of Summative Evaluation
Evaluation Statement

Agree %

Strongly Agree%

1. The selected opioid riskassessment screening tool
is relevant to clinical practice.

36

64

2. The stated problem, purpose
and objectives of the DNP project
were clearly defined.

36

64

3. Project team members were
involved in the policy development
and procedure for the use of the
Opioid Risk Tool.

36

64
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4. Communication was effective
regarding policy and procedure
development.

36

64

5. The patients that should be
screened for risk of prescription
opioid misuse and/or abuse using
the Opioid Risk Tool were clearly
defined.

18

82

6. The recommendations for
implementing a practice change
by adapting the Opioid Risk Tool
are clear and unambiguous.

18

82

7. The policy and procedure will
improve patient care.

64

36

8. The Opioid Risk Tool will be useful
in identifying patients at risk for
prescription opioid misuse and/or
abuse with complaints of pain.

45

55

9. This information presented in this
DNP project increased your knowledge
of prescription opioid misuse and abuse
risk assessment in patients with complaints
of pain.

45

55

10. The DNP student conducted the study
with professionalism.

27

73

11. The DNP student demonstrated
leadership skill throughout the process.

9

91

Simple descriptive statistics were utilized to calculate what percentage of the group rated
each of the 11 on a five -point Likert scale. All 11 team members participated. Overall
team members recommended implementing the policy into clinical practice. The results
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of the summative evaluation reflected that DNP project goals were met and that I lead
this DNP project with leadership skills throughout the process. 64% of the team
responded that strongly agree that the selected ORAST was relevant to clinical practice;
the stated problem, purpose and objectives of the DNP project were clearly defined;
project team members were involved in the policy development and procedure for the use
of the Opioid Risk Tool; and communication was effective regarding policy and
procedure development. Of these four items 26% of the team responded agree. 82% of
the team responded strongly agree to the patients that should be screening for risk of
prescription opioid misuse and/or abuse using the Opioid Risk Tool was clearly defined,
and the recommendation for implementing a practice change by adapting the Opioid Risk
Tool was clear and unambiguous. For these two items 18% of the team responded agree.
36% of the team responded strongly agree to the policy and procedure will improve
patient care while 64% responded agree. Finally, 55% of the team responded strongly
agree and 45% responded agree to the Opioid Risk Tool would be useful in identifying
patients at risk for prescription opioid misuse and/or abuse with complaints of pain.
Since the summative evaluation was anonymous and an area for comments was not
provided, nor were any left I was unable to determine why some stakeholders responded
agree versus strongly agree to each of the 11 items. This was later seen as a limitation.
Overall the results revealed that all 11 participants responded either agree or strongly
agree to each of the 11 items. This concludes that the proposed guidelines can be
recommended for use in practice with the support of the stakeholder team.

60
Potential Implications for Positive Social Change
Through utilization of an ORAST there is a potential implication for positive
social change. Implementation of the ORT into this inner-city ambulatory clinic in the
northeast has the potential to change prescribing practices with the clinic and create
positive social change by allowing for providers to consistently screen patients with
complaints of pain for prescription opioid misuse and abuse prior to initiating
prescription opioid medications. Provider whom utilize an ORAST prior to initiating
prescription opioids have the ability to identify patients that are at risk for prescription
opioid misuse and/or abuse. By understanding each patient’s risk stratification a plan of
care can be developed in order to manage the patient’s pain complaints while taking the
least amount of risk. For example, a plan of care for patients identified as being at high
risk for prescription opioid misuse and/or abuse may include deferring from initiating
opioids and trialing alternative therapies, initiating prescription opioids with intensified
adherence monitoring, and/or referring to a specialist in pain management. This in turn
can assist providers reduce prescription opioid misuse, abuse, exposure, dependence,
addiction, opioid related deaths, and the associated economic burden. This can improve
the quality and safety of patient care within the clinic amongst patients with complaints
of pain.
Strengths and Limitations of the Project
The strengths and limitations of this project were identified. Definite strengths of
this DNP project included the enthusiasm and teamwork of the DNP project team, the
support of the medical director, and the desire of the residents as a whole to create to
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practice change to combat the prescription opioid epidemic. There were several
limitations of the project. The implementation of the Opioid Risk Tool (ORT) and the
policy guiding its use will not occur until after graduation. The medical director
anticipates this to occur in spring of 2018. An additional limitation of this DNP project
was the lack of knowledge amongst the residents in regards to current evidence-based
guidelines and recommendation in treating pain, prescribing opioids, and the adherence
monitoring of prescription opioid medications. According to Nuseir, Kassab, and
Almonani (2016), an integral component of effectively diagnosing and managing patients
with complaints is a comprehensive understanding of pain management, however
providers often reveal a deficit as they are neither knowledgeable nor well educated about
pain. In speaking with the DNP project team, the residents reported that their degrees
focused very little, if at all on pain and/or pain management and they feel ill prepared to
diagnose, treat, and manage patients with complaints of pain both safely and effectively.
According to Volkow and McLellan (2016), more than 30% of Americans have some
form of either acute of chronic pain. Given the frequency the providers encounter needing
to manage pain complaints knowledge continues to be lacking. According to Volkow and
McLellan (2016), many physicians admit that they are not confidence in how to safely
prescribe opioid medications, how to detect prescription opioid misuse and/or abuse, or
how to discuss these problems with their patients. The residents’ lack of knowledge may
have potentially impacted the development of the DNP project and development of the
policy. Another limitation was the absent of anonymity in voting during both round table
discussions. It is possible that the residents may have given different responses during
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voting and discussions if the medical director was not present. Therefore, potential bias
amongst the team in regards to the policy input is possible. Additionally, the participants
did not leave any comments on the AGREE II Instrument. This made it impossible to
identify why certain team members scored domains differently than others. Finally, it
may have beneficial to have an outside pain management expert as part of the stakeholder
team however finding a provider who was able to dedicate their time to the DNP project
in addition to their professional obligations would have proven challenging.
Recommendations
An ORAST, the Opioid Risk Tool (ORT), was introduced to this inner-city
ambulatory care clinic and the policy developed during this project guiding its use will be
implemented after graduation. The medical director is very supportive of implementing
this practice change, and anticipates being able to do so in spring of 2018. The gap in
practice was that, despite guidelines that recommend evaluating risk factors related to
opioids prior to the initiation of opioid medication, providers continued to prescribe them
without consistently assessing the patients. The Opioid Risk Tool (ORT) has been
determined by the stakeholder team and myself to be the most appropriate ORAST for
this ambulatory outpatient clinic. Overall the ORT provides excellent discrimination
between patients at high risk versus low risk for opioid misuse and/or abuse prior to
initiating opioids (Passik et al., 2008). This clinic serves a patient population that is
known to have a history of aberrant behaviors, physical and/or sexual abuse,
psychological illness, and/or a family history of substance abuse (S. Cole, personal
communication, April 21,2017). The ORT consists of five items, which includes family
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history of substance abuse, personal history of substance abuse, age, history of
preadolescent sexual abuse, and psychological abuse. The ORT will allow for patients
that have history of psychological illness, physical or sexual abuse, and substance abuse
history to be appropriately screening for risk of opioid misuse and abuse. Additionally,
the ORT takes less than one minute to be administered by the patient and scored by the
provider, and has been validated in patients with complaints of pain (Passik et al., 2008).
This will not impede provider workflow, and will ensure the information collected from
the ORT is accurate so the providers will feel more confident in relying on the selected
ORAST.
The policy to guide the use of the ORT has been developed and will be used
amongst the residents in their primary care teams after graduation (Appendix E). The
time frame in which this will occur will be decided by the medical director. The
recommendation of the stakeholder team was to implement the ORT as an ORAST in
their practice setting to screen all patients with complaints of pain for opioid misuse
and/or abuse prior to initiating opioid medications. According to the CDC (2016),
reported evidence-based guidelines include evaluating risk factors related to opioid use
prior to initiation of opioid medication. An ORAST has the potential to identify those
patients at risk for opioid misuse and/or abuse. The residents will be responsible for
ensuring the completed ORT is scanned into the respective patient’s electronic health
record. The residents will present the score obtained from the ORT (three or lower is low
risk, four to seven is moderate risk, and eight or higher is high risk) to their attending.
Collaboratively the resident with their attending will develop a customized,
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comprehensive plan of care to based on recommended guidelines to manage the patient’s
pain. According to Jovey (2012), in patients that have a risk of opioid misuse and/or
abuse a provider and a patient may choose to undergo a cautious trial of opioid
medications. The higher the level of risk stratification, the more intense the adherence
monitoring should be. According to Jovey (2012), a patient that is found to be at high risk
for opioid misuse and/or abuse requires a plan of care that includes more monitoring,
structure, and assessment. Each of the10 residents really felt that their knowledge base
differed amongst each other however despite experience level all of the residents
verbalized that they really did not feel knowledgeable in pain management or safe opioid
prescribing. According to Hashemi, Akbari, Razavi, Niaki, and Khameneh, (2015),
residents often have differing degrees of inadequate knowledge and attitudes of pain
management and safe opioid prescribing. As pain is a complaint that surfaces in many
aspects of medicine incorporating pain management into curriculum could help to
improve the quality and safety of care in patients with complaints of pain. According to
Hashemi et al. (2015), medical schools should increase education programs and integrate
education and clinical training for pain management. Both the residents and the medical
director expressed wanting to use the policy’s design as an opportunity for teaching to
increase aptitude for pain management rather than an algorithm for patient care. This will
address the need for further resident education on pain management.
The plan of care agreed upon by the resident and their attending is to be
documented in the patient’s electronic medical record. Post implementation of the
ORAST and the policy to guide its use it was recommended to the medical director that a
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three-month reassessment be completed. Retrospective chart reviews should be
completed amongst patients that were initiated opioid medications during the three-month
post implementation time period to analyze if the ORT was utilized and the policy to
guide its use was followed. This would inform the level of compliance in regards to the
practice change amongst the residents and the success of the DNP project. This
information should then be disseminated to the project team to inform them of the
success of the practice change and allow for revisions to be made if indicated.
Recommendations for future projects include enhancing the resident program
within this inner-city ambulatory care clinic by providing greater learning opportunities
in regards to pain management. Additionally, projects that outline algorithms that guide
the plan of care of patients with complaints of pain based on risk stratification may also
prove useful.
Summary
Section 4 reported the findings and implications of the data, described the
proposed recommendations, summarized the Doctoral project team, and discussed the
strengths and weaknesses of the project. Section 5 will identify the plan for dissemination
and provide an analysis of self.
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Section 5: Dissemination Plan
Introduction
Implementation of the chosen ORAST, the Opioid Risk Tool (ORT), and the
policy guiding its use will be implemented after graduation. The medical director will
decide as to when the implementation of the ORT and the policy guiding its use will be
introduced to the primary care residents within the clinic. The results of this project
would be appropriate for other audiences and venues, for example professional
publications and presentations to other inner-city ambulatory clinics with similar patient
populations.
Analysis of Self
In the following sections I will analyze myself across several domains related to
developing this DNP project. I will also discuss the completion of the project, challenges
and solutions, and insights gained.
As a Practitioner
This DNP project allowed me to transition as an expert within my field as a nurse
practitioner. Having the opportunity to experience being a leader within a
multidisciplinary team in order to analyze and synthesize literature, disseminate findings,
and pose recommendations allowed me help improve the health outcomes of others by
putting evidence based guidelines into practice. Creating positive social change within
communities is a fundamental component of my long-term professional goals.
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As a Scholar
This DNP project has allowed me to develop and apply new skills. Additionally,
it has improved my ability to analyze and synthesize literature to identify gaps in practice
and then devise interventions to improve the healthcare of others based on their specific
needs. Healthcare is constantly evolving and in order for population health outcomes to
improve research findings need to be put into practice. This DNP project has equipped
me with the tools necessary to do this in a variety of settings so I may be an agent for
positive social change.
As a Project Developer
This DNP project and related coursework allowed me to develop and apply skills
learned in order to utilize theoretical frameworks to implement a practice change to
address a practice problem. One specific skill that I was able to apply was my leadership
skills as this project has allowed me the opportunity to identify an objective and path to
achieve those objectives. This project has also allowed me to develop and apply
management skills while focusing on the implementation of the project while controlling,
arranging, and directing resources. This DNP project has also allowed me to become an
effective team leader and agent for social change. I believe that this DNP project has
helped prepare me to work within the highest level of my degree.
Project Completion
Utilization of an ORAST can change the prescribing practices of clinic providers
and create positive social change. It can do so by reducing the amount of opioids that are
prescribed, identifying patient at risk for prescription opioid misuse and abuse, tailoring
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adherence monitoring to each patient’s risk stratification according to policy. If this is
done, it will reduce opioid misuse, abuse, dependence, addiction, opioid-related deaths,
and the associated societal economic burden.
The goal of this project was to setup the framework to have 100% of the primary
care providers utilize the selected ORAST prior to initiating opioid treatment. Through
completing a systematic and comprehensive review of the literature the Opioid Risk Tool
(ORT) was selected as the ORAST that best fit the needs of the clinic. Through
collaborating with the project team a policy to guide the use of the ORT was created.
Implementation will be completed after graduation. This DNP project has successfully
met its goals.
As with any project there are challenges that can be identified. The greatest
challenge that this DNP project was faced with was the lack of knowledge amongst the
residents in terms of pain management. Although they had varying degrees of experience,
all expressed feeling ill prepared to both effectively and safely manage patients with
complaints of pain. Another limitation of this DNP project was the available resources of
this inner-city ambulatory clinic. As the primary care needs of the clinic are divided
amongst 10 resident based primary care teams, the residents may rotate from team to
team based on staffing needs. Additionally, there is constant turnover as residents
complete their residencies, change programs, or are given other assignments. Due to the
constant resident rotation and turnover patients are often confronted with seeing a
multitude of providers, which inhibits building a patient-provider relationship as well as
continuity of care. Additionally, at this time this clinic meets the needs of its primary care
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patients by solely utilizing residents. A limitation was the inability to better utilize an
interdisciplinary approach. This DNP project has allowed me to develop and strengthen
my leadership skills. I have learned how important selecting and involving a stakeholder
team to be apart of a practice change can be. Without their involvement this DNP project
would be destined to fail. As a leader I have learned the importance of identifying clear
objectives and a path to achieving them, while creating an environment that supports
translation of evidence into practice to support positive social change.
Summary
Through my scholarly journey that has lead me to the completion of this doctoral
project I sincerely feel that positive social change will occur with implementation of the
recommended practice change. One consistent method to assessing patients for
prescription opioid misuse and abuse is to screen with an ORAST. The Opioid Risk Tool
(ORT) has been the selected ORAST to be adapted by this inner-city ambulatory clinic.
The policy to guide its use will be implemented after graduation. The medical director
will be the final decision maker in determining when the policy to guide the use of the
ORT will be implemented. The medical director supports the recommended practice
change to include the selection of the ORT as clinic’s ORAST and the policy designed to
guide its use. He anticipates being able to implement the policy by spring of 2018. It is
recommended that data is gathered three-months post implementation on the ORT and
the policy to guide its use in order to determine if residents are adherent to the practice
change so this information can be disseminated to the team, and further revisions can be
made if indicated.
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Implementation of the ORT into this inner-city ambulatory clinic in the northeast
has the potential to change prescribing practices within the clinic and create positive
social change by reducing the amount of opioids that are prescribed, and tailor adherence
monitoring specifically to each patient’s risk stratification through a policy to guide the
providers in the use of the tool. Limiting the amounts of opioids that are prescribed and
identifying patients at risk for opioid misuse and abuse prior to initiating opioids
management may decrease opioid misuse, abuse, dependence, addiction, exposure, opioid
related deaths, and the associated economic burden.
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Appendix A: Opioid Risk Tool
This tool should be administered to patients upon an initial visit prior to beginning opioid
therapy for pain management. A score of 3 or lower indicates low risk for future opioid
abuse, a score of 4 to 7 indicates moderate risk for opioid abuse, and a score of 8 or
higher indicates high risk for opioid abuse.

Mark each box that applies
Family history of substance abuse
Alcohol
Illegal drugs
Rx drugs
Personal history of substance abuse
Alcohol
Illegal drugs
Rx drugs
Age between 16 – 45 years
History of preadolescent sexual abuse
Psychological disease
ADD, OCD, bipolar, schizophrenia
Depression
Scoring Totals

Female

Male

1
2
4

3
3
4

3
4
5
1
3

3
4
5
1
0

2
1

2
1

Questionnaire developed by Lynn R. Webster, MD to assess risk of opioid addiction

Webster, LR., & Webster, RM. (2005). Predicting aberrant behaviors in opioid-treated
patients: preliminary validation of the Opioid Risk Tool. Pain Medicine, 6(6):
432-442. doi: 10.1111/j.1526-4637.2005.00072.x
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Appendix B: Opioid: Disclosure to Expert Panelist Form for Anonymous Questionnaires
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Appendix C: AGREE II Instrument
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Appendix D: Summative Evaluation
Opioid Risk-Assessment Screening Tool
Summative Evaluation
Circle the numeric response to each question

#

Question

Survey Scale
(5) Strongly Agree, (4) Agree, (3)
Neural, (2) Disagree, (1) Strongly
Disagree

1
2

3

The selected opioid risk assessment-screening tool is
relevant to clinical practice.
The stated problem, purpose, and objectives of the
DNP Project were clearly defined.

Project teams members were involved in policy
development and procedure for the use of the Opioid
Risk Tool.
4 Communication was effective regarding policy and
procedure development.
5 The patients that should be screened for risk of
prescription opioid misuse and/or abuse using the
Opioid Risk Tool were clearly defined.
6 The recommendations for implementing a practice
change by adapting the Opioid Risk Tool are clear and
unambiguous.
7 The policy and procedure will improve patient care.
8 The Opioid Risk Tool will be useful in identifying
patients at risk for prescription opioid misuse and
abuse with complaints of pain.
9 This information presented in this DNP Project
increased your knowledge of prescription opioid
misuse and abuse risk assessment in patients with
complaints of pain.
10 The DNP student conducted the study with
professionalism.
11 The DNP student demonstrated leadership skills
throughout the process.

5

4

3

2

1

5

4

3

2

1

5

4

3

2

1

5

4

3

2

1

5

4

3

2

1

5

4

3

2

1

5
5

4
4

3
3

2
2

1
1

5

4

3

2

1

5

4

3

2

1

5

4

3

2

1
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Appendix E: Opioid Risk Tool Policy
Title: Opioid Misuse and Abuse Screening Prior to Opioid Initiation Policy
Section: Medications
Number:
Effective Date:
Medical Director Signature:

1.0 Purpose:
To consistently screen patients with complaints of pain for opioid misuse and
abuse prior to the initiation of opioid medications. Considering proper opioid
prescribing includes assessing the potential risk of opioids in order to reduce
opioid misuse, abuse, addiction, dependence, overdose, and exposure (CDC,
2017) all patients with complaints of pain will first be screened using an opioid
risk-assessment screening tool prior to being prescribed any/all opioids.
2.0 Policy
This policy will provide guidelines for the use of the Opioid Risk Tool.
3.0 Supportive Data:
4.0 Equipment and Forms
4.1 Opioid Risk Tool (see attached exhibit)
5.0 Procedure: All primary care residents will first screen patients for opioid
misuse and abuse using the Opioid Risk Tool (ORT) prior to initiating any/all
opioid medications. The completed ORT will be scanned into the patient’s
electronic medical record. Based on the score obtained from the ORT patients will
be ranked as low risk (3 or lower), moderate risk (4 – 7) or high risk (8 or higher)
for risk of opioid misuse and/or abuse. The resident will present the completed
ORT to their attending and the corresponding patients case to their attending.
Collaboratively the resident with their attending will develop a customized,
comprehensive plan of care to manage the patient’s pain. The plan of care agreed
upon by the resident and their attending is to be documented in the patient’s
electronic medical record.
6.0 Documentation: The completed ORT is to be scanned into the patient’s
electronic medical record and the resident’s and their attending’s agreed upon
plan of care must be documented into the patient’s chart.
7.0 References and Resources:
7.1 Center for Disease Control and Prevention. (2017). Guideline information for
providers. Retrieved from
https://www.cdc.gov/drugoverdose/prescribing/providers.html
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7.2 Webster, LR., & Webster, RM. (2005). Predicting aberrant behaviors in
opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain
Medicine, 6(6): 432-442. doi: 10.1111/j.1526-4637.2005.00072.x

